The short answer on CBG and glaucoma
There is no reliable clinical evidence that CBG (cannabigerol) lowers intraocular pressure or slows glaucoma. Glaucoma is managed with prescription drops, laser treatment, and surgery, and no cannabinoid, including CBG, is an accepted substitute for those treatments. Anyone asking about CBG benefits for glaucoma should know that the science here is early, indirect, and mostly done on cells and animals rather than people.
That does not mean cannabis research is irrelevant to eye health. It means the gap between "a cannabinoid affects a pathway in a lab dish" and "this helps a person keep their vision" is wide, and CBG has not crossed it.
What CBG is and why it gets mentioned
CBG is a minor cannabinoid found in cannabis, and it is the chemical precursor that plants convert into CBD and THC as they mature. Because it interacts with the body's endocannabinoid system, researchers have looked at it for pain, inflammation, and gut conditions. Glaucoma enters the conversation because the eye contains cannabinoid receptors and because cannabinoids can influence fluid drainage and blood vessel tone.
- CBG content in most flower is low. Getting a meaningful dose usually means extracts or isolated products.
- CBG is not psychoactive in the way THC is, which makes it easier to study and easier to use during the day.
- Most CBG eye research is preclinical. Human trials specific to glaucoma are essentially absent.
What the research on cannabinoids and eye pressure shows
The best known findings involve THC, not CBG. Smoked or ingested THC can lower intraocular pressure for a short window, roughly a few hours, which is far shorter than the 24 hour control that glaucoma requires. Repeated dosing to maintain that effect would mean being impaired throughout the day, and the pressure-lowering effect tends to fade with regular use.
CBD data point in a different direction. Some small human studies have reported that oral CBD raised intraocular pressure rather than lowering it, which is the opposite of what someone with glaucoma would want. CBG sits in an even thinner evidence base: laboratory work suggests it may affect fluid dynamics and ocular blood flow, but nobody has shown a durable, clinically meaningful pressure drop in patients.
Two practical points follow from this:
- A few hours of lower pressure does not protect the optic nerve the way a daily drop regimen does.
- Glaucoma usually has no symptoms until vision is already lost, so experimenting with unproven products risks silent damage.
Risks and interactions to keep in mind
CBG is generally described as well tolerated in small studies, but "generally well tolerated" is not the same as "safe for you." Considerations include:
- Delayed care. The biggest risk is substituting a cannabinoid for proven treatment and losing vision that could have been preserved.
- Medication interactions. Cannabinoids are processed by liver enzymes that many prescriptions also use, including some blood pressure drugs.
- Blood pressure and dizziness. Cannabis can lower blood pressure, which matters for people on antihypertensives.
- Product variability. Labels on cannabis products do not always match actual cannabinoid content, so dosing is imprecise.
- Pregnancy, heart conditions, and certain psychiatric histories warrant a conversation with a clinician before use.
How to think about CBG if you have glaucoma
Keep your ophthalmologist in the loop and treat CBG as a comfort or wellness product, not a treatment. Continue prescribed drops and follow your monitoring schedule, including pressure checks and visual field testing. If you use CBG, note the dose, product, and timing so you can report anything unusual. Ask whether your current regimen has room to improve before adding anything unproven, since adherence to drops is the most common reason glaucoma progresses.
If you are shopping legally in a state where cannabis is regulated, choose products with third-party lab testing and clear cannabinoid panels. That gives you a better sense of what you are actually consuming, even when the therapeutic question remains unanswered.